MedTrace Logo

A Phase I Clinical Study of VC005 Tablets in Subjects With Rheumatoid Arthritis.

NCT05874622 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2023-11-03

No results posted yet for this study

Summary

This is a randomized, double-blind, dose-escalating, placebo-controlled phase Ib clinical study.

Conditions

Interventions

DRUG

VC005 tablets

VC005 groups repeat administration for 4 weeks

DRUG

VC005 Tablets Placebo

VC005 placebo groups repeat administration for 4 weeks

Sponsors & Collaborators

  • Jiangsu vcare pharmaceutical technology co., LTD

    lead INDUSTRY

Principal Investigators

  • Yanhua Ding · The First Hospital of Jilin University

  • Nanya Wang · The First Hospital of Jilin University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-12
Primary Completion
2023-10-18
Completion
2023-10-25

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05874622 on ClinicalTrials.gov